0.13
+0.0006(+0.48%)
Currency In USD
| Previous Close | 0.12 |
| Open | 0.12 |
| Day High | 0.13 |
| Day Low | 0.12 |
| 52-Week High | 21.4 |
| 52-Week Low | 0.12 |
| Volume | 11.46M |
| Average Volume | 10.37M |
| Market Cap | 1.82M |
| PE | 0 |
| EPS | -87.25 |
| Moving Average 50 Days | 0.44 |
| Moving Average 200 Days | 3.35 |
| Change | 0 |
If you invested $1000 in Onconetix, Inc. (ONCO) since IPO date, it would be worth $0.05 as of March 20, 2025 at a share price of $0.125. Whereas If you bought $1000 worth of Onconetix, Inc. (ONCO) shares 2 years ago, it would be worth $3 as of March 20, 2025 at a share price of $0.125.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
GlobeNewswire Inc.
Yesterday at 12:00 PM GMT
CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech, Inc. (BWV)), a cancer diagnostics company focused on the research, development and commercialization of in
Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing
GlobeNewswire Inc.
Dec 12, 2024 10:00 PM GMT
Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq Capital Market (“Nasdaq”) on December 6, 2024 indicating that the Company’s failure to file its Qua
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit
GlobeNewswire Inc.
Oct 03, 2024 8:45 PM GMT
CINCINATTI, OH., Oct. 03, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Onconetix, Inc. (Nasdaq: ONCO), please note that in the first paragraph of the release, the name of the financial advisor to Onconetix i